A big shout out to Cytovation AS!

Whom recently announced clinical trial collaboration and supply agreement with Merck to evaluate the safety and efficacy of CyPep1 in combination with KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy.

With phase 1 monotherapy data of CyPep-1 showing a strong safety profile and encouraging anti-tumour activity, Cytovation AS is on its way on developing treatment of multiple diseases, ranging from benign tumors to malignant cancers. Project Sandwater continues to be excited for the future as we join in on the shared journey forward.

Read full article on PR Newswire.com